Researchers conducted a randomized clinical trial to test the efficacy of a hybrid closed-loop (HCL) system among pediatric patients with type 1 diabetes (T1D).
Six months of hybrid closed-loop (HCL) therapy significantly improved glycemic control and quality of life among children and adolescents with type 1 diabetes (T1D) when compared with conventional therapy, according to results of a randomized clinical trial. Findings were published in JAMA Pediatrics.
“The HCL system uses a control algorithm that delivers insulin based on continuous glucose monitoring (CGM) glucose measures,” authors explained. “However, meals must still be announced and an insulin bolus delivered according to meal carbohydrate content.” Previous research found this system improved glycemic measures, compared with standard therapy, in adults with T1D.
To evaluate the HCL’s long-term efficacy in children and adolescents with T1D and to address the psychosocial outcomes of use, researchers conducted a 6-month trial in Australia. Specifically, they compared the percentage of time in range (TIR) for the target glucose range (70 to 180 mg/dL) using HCL vs the currently available conventional therapies (continuous subcutaneous insulin infusion [CSII] or multiple daily injections [MDI] with or without CGM).
Between April 2017 and October 2019, investigators recruited 135 patients from 5 tertiary pediatric diabetes centers in Australia. Following a 5-week run-in phase, participants were randomly assigned to the control or intervention (HCL) groups for 26 weeks. In addition, masked CGM data were collected at baseline (3 weeks), midstudy (2 weeks), and study end (3 weeks), researchers said.
Mean (SD) participant age was 15.3 (3.1) years and the majority were girls (56%). Sixty-eight patients were randomized to the control group and 67 to the HCL group, while patients had a mean diabetes duration of 7.7 (4.3) years and a mean glycated hemoglobin (HbA1C) of 64(11) mmol/mol.
Analyses revealed:
“In our study, the improvement in TIR was seen across both day and night and was associated with a reduction in hypoglycemia and glycemic variability, albeit with no reduction in hyperglycemia,” authors wrote.
Researchers hypothesized improved quality of life scores reported among HCL uses could be due to factors like reduced worry, increased confidence and trust in the system with improved glycemic control, and increased ownership of diabetes management.
As the trial was conducted by tertiary centers with technology expertise, results may not be generalizable to the wider public, marking a limitation. In addition, researchers were unable to assess the degree of engagement with CGM devices of participants in the control group.
“To our knowledge, this is the first randomized clinical trial in youth with T1D to provide conclusive evidence that HCL improves glycemic outcomes and quality of life in youth with T1D,” authors concluded. “The HCL system represents an important step in the pursuit of technological advancements toward a fully automated closed-loop system.”
Reference
Abraham MB, de Bock M, Smith GJ, et al. Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial. JAMA Pediatr. Published online October 11, 2021. doi:10.1001/jamapediatrics.2021.3965
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Study Suggests Walking 10K Steps Daily Improves QOL in Severe Hemophilia
April 12th 2024Among a small group of patients with severe hemophilia, researchers found that getting in more than 10,000 steps each day was linked to significant improvements in perceived physical health and quality of life (QOL).
Read More
Bioinformatics, Machine Learning Reveal New Insights Into MG-Associated DCM
April 11th 2024Researchers explain that these insights have important implications, if validated in further research, as challenges with early detection of dilated cardiomyopathy complicate myasthenia gravis (MG)-prognosis.
Read More